Juvenile dermatomyositis (JDM) is a rare but complex and potentially lifethreatening autoimmune disease of childhood, primarily affecting proximal muscles and skin. Although the cause of JDM remains unknown it is clear that genetic and environmental influences play a role in the aetiology. In contrast to adults with dermatomyositis, children with JDM are more likely to have complications that are thought to indicate a vasculopathic process, such as severe skin disease, with ulceration or calcinosis, gut vasculopathy or central nervous system disease. New treatments are much needed and are becoming available and being tested through international multicentre trials. This review will focus on recent insights into pathogenesis, the assessment of the disease in children and the modern approach to its treatment.
Introduction
Juvenile dermatomyositis (JDM) is a rare but serious systemic autoimmune condition of childhood primarily affecting proximal muscles and skin. Polymyositis and inclusion body myositis are rare in children. Although historically many clinical studies concentrated on muscular features, the cutaneous manifestations of JDM can be serious and difficult to treat and may progress to ulcerative disease and or subcutaneous calcification, impacting seriously on quality of life in the long term.
JDM has an incidence of approximately 3.2 per million children per year in the UK with differences between ethnic groups, and is at least three times more common in girls than boys [Feldman et al. 2008; Symmons et al. 1995] . The mean age of onset is 7 years [Martin et al. 2011a ], although about 25% of patients with JDM present under the age of 5 years.
Unlike the adult idiopathic inflammatory myopathies (IIM), JDM is generally thought not to be a paraneoplastic phenomenon. In the UK JDM Cohort study (currently n = 336 patients) there have been no neoplasms reported in association with childhood myositis in a 12-year data collection period, although long-term follow up of these patients will be important to validate this finding. A recent literature review including studies from the past 15 years [Morris and Dare, 2010] described a handful of patients in whom unusual physical findings such as splenomegaly or lymphadenopathy were noted on diagnosis, and in whom a primary malignancy was found within 12 months of diagnosis.
Assessment of suspected cases of juvenile inflammatory myositis
Children with suspected inflammatory myositis are ideally cared for in specialist centres where there is easy access to an experienced multidisciplinary team, including paediatric rheumatologists and neurologists, specialist nurses, physiotherapists, speech therapists, dermatologists, muscle histopathologists and also access to imaging and other investigations. The increasingly common model of providing care through networks of specialists who share expertise and knowledge should improve the care of these complex patients, although delay in access to specialist care remains an issue [Martin et al. 2011a ].
Although the criteria for diagnosis still used for many studies are still those of Bohan and Peter Peter, 1975a, 1975b] these criteria have been shown to be no longer reflective of Juvenile dermatomyositis: new insights and new treatment strategies modern day paediatric practice, since many paediatricians do not choose to perform electromyography on children, and some centres no longer routinely perform muscle biopsy [Brown et al. 2006 ]. Clinical examination should include formal assessment of muscle strength using a validated tool, such as the Childhood Myositis Assessment Scale (CMAS) or manual muscle testing of the standardized eight groups of muscles (MMT8) [Huber, 2010; Huber et al. 2004; Lovell et al. 1999 ]. In addition, careful assessment of the skin is mandatory, and this should include nail fold capillary examination. Two skin score systems for the assessment of skin involvement in JDM have been proposed. The Disease Activity Score (DAS) for JDM includes assessment of skin and muscle involvement and distribution of rash. It has good reliability and scores correlate with periungual nailfold capillary changes [Bode et al. 2003; Smith et al. 2004 ]. The Cutaneous Assessment Tool (CAT) assesses skin disease in myositis by considering activity in 10 lesions, damage in four lesions and a combination of activity and damage in seven lesions. The tool has been partially validated in a large JDM population and demonstrated good reliability, content and construct validity, and responsiveness [Huber and Feldman, 2005; Huber et al. 2008a Huber et al. , 2008b . Assessment of other organ systems, including respiratory, gastrointestinal, speech and language is also critical. The investigation of a child suspected of having an inflammatory myopathy should include magnetic resonance imaging (MRI) of muscles in a specialist centre with experience of interpretation of such images. The degree of muscle change on MRI can be quantified on T2 STIR images and has been shown to correlate with disease activity . While classical proximal muscle weakness is typical, it is also important the child undergoes thorough investigation for other organ involvement, such as of the gastrointestinal tract, including a speech and swallowing assessment [McCann et al. 2007] or respiratory system (typically a high-resolution computed tomography scan). In addition to MRI, some centres still perform biopsy, most usually from quadriceps or biceps muscle; a proposed muscle score tool assessing pathological severity in four domains (inflammation, vasculopathic change, muscle fibre and connective tissue) has been shown to have good interobserver reliability and to correlate with clinical severity [Wedderburn et al. , 2010 [Wedderburn et al. , 2011 .
Two international groups of investigators, the Paediatric Rheumatology International Trials Organization (PRINTO) and the International Myositis Assessment and Clinical Studies Group (IMACS) have proposed a core set of tools for the assessment of disease activity and damage in JDM [Miller et al. 2001; Ruperto et al. 2003 Ruperto et al. , 2008 . Such core outcome variables include an overall physician assessment and a parent/patient assessment by visual analogue or Likert scale, a measure of functional ability typically using the Child Health Assessment Questionnaire (CHAQ), assessment of muscle strength using CMAS or MMT8, laboratory variables (creatine kinase, lactate dehydrogenase, erythrocyte sedimentation rate) and assessment of disease activity that captures extramuscular disease (the DAS or the Myositis Disease Activity Assessment Tool, MDAAT) [Wedderburn and Rider, 2009 ]. The Myositis Damage Index is another potentially useful tool which has recently been validated in both adult and paediatric populations for the assessment of disease-related damage in patients with dermatomyositis [Isenberg, 2004; Rider et al. 2011] . As the collection of such data items becomes more routine in specialist centres and beyond, the comparison of outcomes between different treatment protocols and regimes, as well as in clinical trials, will become possible.
Aetiology and pathogenesis of juvenile dermatomyositis

Genetics
As for many autoimmune rheumatic diseases, JDM is thought to arise from a complex interplay of immunological dysfunction resulting from environmental stimuli in genetically susceptible patients. The inflammatory myopathies are complex polygenic disorders, and the identification of specific genetic loci has been hampered by the rarity of these diseases. With the establishment of multicentre collaborations and registries we are not only beginning to understand the intricacies of both protective and susceptible alleles within the highly polymorphic human leukocyte region (HLA) region, but have identified other regions of interest, including proinflammatory cytokine genes, lymphocyte signalling genes [Chinoy et al. 2008 ] among others. Within the HLA region, one of the most highly polymorphic regions of the human genome, there are allelic variants associated with increased risk for many autoimmune diseases, including JDM. Thus HLA-B*08, DRB1*0301, and DQA1*0501 are part of a haplotype that confers risk of myositis in both children and adults, in white people [Chinoy et al. 2009a; Mamyrova et al. 2006; Reed et al. 1991; .
Recent work has shown that HLA-DPB1*0101 also confers independent risk of myositis in particular serological subgroups [Chinoy et al. 2009b ] and that the DQA1*0301 allele is an additional risk factor for JDM. Interestingly there are strong associations between specific risk alleles and the serological phenotype [Chinoy et al. 2006 ], suggesting that T-cell help of specific autoreactive B cells may play a key role in early pathological events.
Genetic factors have been associated with specific manifestations, disease susceptibility and severity in both adult onset myositis syndromes and JDM. The tumour necrosis factor α variant, TNFα-308A, carries a higher risk of prolonged disease course, calcinosis and ulcerative skin disease, although there is controversy about whether this may be in part due to linkage disequilibrium with the HLA-B locus [Chinoy et al. 2007 ]. The presence of the TNFα-308A allele in conjunction with an osteopontin promoter polymorphism (rs28357094G) has been found to be associated with high serum interferon-γ activity in the serum from untreated patients with JDM of European ancestry in a subset of patients who exhibit a more severe disease phenotype and are more likely to develop skin calcinosis. The TNFα-308A allele itself has previously been shown to be associated with vascular occlusion [Lutz et al. 2002] and increased TNFα production [Pachman et al. 2001] ; however, an interleukin (IL)-1 polymorphism [Mamyrova et al. 2008 ] also seems to confer additional risk of calcinosis [Lutz et al. 2002] .
The strong associations with HLA allelic differences and a genetic association with the T-cell signalling molecular PTPN22 [Chinoy et al. 2008] all suggest a key role for T cells in the pathogenesis of JDM. Certainly, immune dysregulation in innate, humoral and cellular responses have all been described in JDM [Elst et al. 2008; O'Connor et al. 2006; ]. Recent studies have also implicated nonimmune mechanisms that may involve molecules typically identified with an immunological role, for example major histocompatibility complex (MHC) class I [Li et al. 2009; Nagaraju et al. 2005] in the pathogenesis of adult IIM and JDM. The interplay between these systems may offer novel therapeutic targets.
Humoral and cellular immunity
Historically, myositis-specific and myositis-associated autoantibodies were thought to be rare in JDM. However, when full testing methodology is employed serological analysis from large cohorts achieved through national and international collaborations seem to contradict this view, identifying up to 70% of patients who show specific autoantibody responses ]. As in adults, the majority of antigenic targets of the specific autoantibodies associated with JDM are cytoplasmic or nuclear proteins involved either in protein synthesis (e.g. the tRNA synthetase enzymes), or gene regulation.
Certain myositis-specific antibodies and their associated clinical phenotype hold true across age groups, when children with JDM mirror manifestations in adult patients with IIM; for example, anti-PM-Scl with scleroderma overlap features, anti-Mi-2 with classic skin rash of dermatomyositis, and antihistidyl RNA synthetase (Jo-1) with interstitial lung disease ]. Other associations diverge. A novel anti-p155/140 represents autoantibodies to a 155-kDa and a 140-kDa protein found in 23-29% of patients with JDM, which are associated with an increased risk of cutaneous disease and a prolonged course in JDM [Gunawardena et al. 2008 ]. Furthermore, the same group has found a different autoantibody anti-p140 associated with the development of calcinosis in children with JDM [Gunawardena et al. 2009 ]. Whether these particular antibodies predate the specific features with which they associate and therefore could be used as prognostic biomarkers remains to be defined. This remains an area of active research, with ultimately the identification of these autoantibodies possibly offering more than mere prognostication in the condition but specifically targeted therapy.
Some autoantibodies are thought to confer a role in the pathogenesis of myositis, although the paradox of how such antibodies lead to muscle damage, given that the antigens which are in general ubiquitously expressed is yet unresolved. Several elegant studies have demonstrated specific upregulation of the autoantigens in regenerating myoblasts or the ability of these autoantibodies to promote proinflammatory type l interferon activation [Eloranta et al. 2007] or chemotaxis [Howard et al. 2002] .
A recent study has suggested a specific link between T-cell and B-cell immunity in JDM, by showing that T-follicular helper cells (which are CXCR5 positive) are over represented in the blood of patients with JDM, are heavily skewed towards IL-17 production, and that these T cells can provide a potent role in driving antibody production by B cells [Morita et al. 2011] .
Endoplasmic reticulum (ER) stress
Since the identification of MHC class I overexpression on muscle cells in IIM over 25 years ago [Isenberg et al. 1985] , this abnormality has remained an important and sensitive, although not specific, feature for diagnosis of IIM on biopsy features, including for JDM [Li et al. 2004; ]. This observation prompted the generation of a transgenic murine model in which expression of self-MHC class l in muscle tissue leads to myositis [Nagaraju et al. 2000 ]. When this model was adapted, by induction of the disease in very young mice, to reflect JDM, results suggested an increased susceptibility of very young muscle to the effects of overexpression of MHC. The high levels of MHC class l protein lead to activation of the endoplasmic reticulum stress response, itself highly proinflammatory, and consequent muscle damage [Li et al. 2009 ].
Innate immunity
Endothelial dysfunction is another important aspect in JDM and lies behind some of the most devastating and life-threatening complications. Capillary loss is a feature of early biopsy changes and is thought to be associated with poor prognosis [Christen-Zaech et al. 2008; Emslie-Smith and Engel, 1990; Smith et al. 2004] . Antibody deposition and complement activation on small vessels both in muscle and other tissues is implicated when various cytokines and chemokines (IL-1, intercellular adhesion molecule-1, vascular cell adhesion molecule, CXCL10) [Fall et al. 2005; Lundberg et al. 1997; Sallum et al. 2004] have been identified in inflamed muscle tissues, which may propagate the disease process.
Heterogeneous populations of dendritic cells (DCs) may also play a pivotal role in the pathogenesis of IIM. Not only have mature DCs been identified in inflamed muscles [López de Padilla et al. 2007 ], but in addition, a recent study showed mature dendritic cells and mast cells present in involved and uninvolved skin from patients with JDM . Both cell types are capable of driving the type I interferon response; the propensity of the former is also associated with more severe clinical disease [López De Padilla et al. 2009 ].
Current treatments and new developments in therapy for juvenile dermatomyositis
Initial therapy
Over the past five decades steroid-based treatment strategies have transformed the prognosis for children with JDM. Before 1960, one-third of patients with JDM would die and one-third developed severe disability [Bitnum et al. 1964; Huber and Feldman, 2005] while the current estimated mortality for JDM is less than 2% [Huber et al. 2000 ]. Steroids remain the basis of initial therapy for patients with JDM and early aggressive therapy has been associated with improved outcome; however, uncertainty remains over the optimum therapeutic strategy and to what extent severity of disease at presentation should guide treatment. Vasculopathic involvement of the proximal intestine in JDM has been shown to reduce absorption and bioavailability of enteral corticosteroids [Rouster-Stevens et al. 2008] . As a result, it has been suggested that aggressive initial treatment with intravenous methylprednisolone may be superior to traditional steroid regimens based on oral prednisolone [Fisler et al. 2002] . To date, there have been no prospective clinical trials to confirm this. One retrospective nonrandomized comparative study found no difference in a number of important outcome measures between patients treated with aggressive therapy using either intravenous methylprednisolone or highdose oral prednisolone (5-30 mg/kg/day) versus treatment with standard-dose oral prednisolone (1-2 mg/kg/day) [Seshadri et al. 2008] . Two further retrospective case series reported that the use of intravenous methylprednisolone was associated with significant reductions in duration of active disease, disease-related costs and other complications, including calcinosis [Fisler et al. 2002; Klein-Gitelman et al. 2000 ]. A single-centre retrospective study from North America reported 49 patients with JDM treated with a standardized protocol. This involved patients with moderate or severe weakness receiving three initial doses of intravenous methylprednisolone followed by methotrexate, oral prednisolone and weekly intravenous methylprednisolone until muscle enzymes and strength normalized. Patients treated by this aggressive protocol had improved outcomes and reduced disease-related complications compared with historical controls, including drugfree remission in 57% of patients with a median time to inactive disease of 38 months and persistent calcinosis in 4% of patients [Kim et al. 2009 ].
A recent, large survey of paediatric rheumatologists throughout North America and Canada found that most respondents would treat moderate or severe JDM with parenteral steroids initially and the majority would treat mild JDM with oral steroids initially [Stringer et al. 2010 ]. This pragmatic approach in the absence of prospective evidence appears to reflect an underlying belief that patients with apparently mild skin and muscle disease are less likely to have significant intestinal vasculopathy. The same survey found that most patients were treated with a combination of steroids and methotrexate regardless of severity and that methotrexate was usually given by the subcutaneous route. These results are similar to data from a survey of paediatric rheumatology centres throughout the UK [Martin et al. 2011b] , which also found that most centres would use a combination of methotrexate and steroids as initial therapy for JDM irrespective of severity. A retrospective study comparing patients treated at the same centre before and after instigating a policy of treating with methotrexate showed that children treated with methotrexate received significantly less steroids with a median duration of steroid treatment of 10 months versus 27 months in the group treated without methotrexate [Ramanan et al. 2005] . Perhaps unsurprisingly, the group who received methotrexate developed less steroidrelated side effects. Although steroids and methotrexate clearly form the basis for current therapy in North America and the UK, firm evidence to support this is lacking and treatment strategies vary in other parts of the world. Results should soon be available from a large, prospective multicentre randomized controlled trial (RCT) run by PRINTO comparing corticosteroids versus corticosteroids with methotrexate versus corticosteroids with cyclosporine (www.printo.it). Other treatments given as initial therapy by some centres include intravenous immunoglobulin (IvIg) and hydroxychloroquine [Stringer et al. 2010] .
Cyclophosphamide
A retrospective case series of 12 patients treated with intravenous cyclophosphamide for severe JDM showed a good response in all survivors [Riley et al. 2004] . Two patients died who already required ventilation for severe disease prior to receiving treatment and there was no evidence of serious cyclophosphamide related toxicity in the short term. Data from the recent UK and North American surveys suggest that the use of cyclophosphamide is reserved as a treatment for severe disease, pulmonary involvement, ulcerative skin disease or wider systemic involvement. In the UK it is often used as initial therapy for these patients whereas in North America it is usually reserved for patients whose condition fails to respond to standard therapy.
Treatment of refractory disease
IvIg was associated with both clinical and histological improvement in a prospective crossover double-blind RCT of patients with refractory adult myositis [Dalakas et al. 1993; Al-Mayouf et al. 2000 ]. Data from both the UK and North America [Martin et al. 2011b; Stringer et al. 2010] suggest that most paediatric rheumatologists reserve IvIg for patients with an inadequate response to first-line therapy.
Raised levels of TNFα have been associated with a chronic disease course and calcinosis in JDM [Pachman et al. 2001] . A case series of five patients successfully treated with infliximab for calcinosis and JDM refractory to standard therapy has been described [Riley et al. 2008] . Our recent survey suggests that anti-TNFα therapy has become the most commonly considered second-or third-line therapy for patients with refractory JDM in the UK [Martin et al. 2011b ].
In addition to blockade of TNFα, other biological therapies have also been tried in severe and refractory cases of JDM. Given the increasing information regarding the importance of novel autoantibodies in the pathogenesis of JDM, it has been hoped that B-cell depletion with agents such as rituximab may prove to be effective. An initial case series of patients with JDM treated with rituximab showed clinical improvement in three out of four patients [Cooper et al. 2007] . Results from a prospective RCT with a crossover design including patients with both adult and juvenile dermatomyositis are likely to be available soon.
Mycophenolate mofetil (MMF) has been shown to be an efficacious treatment in renal and extra renal lupus [Posalski et al. 2009 ] and profiling of blood from patients with JDM has shown some important similarities to systemic lupus erythematosus, particularly with regard to type 1 interferon-induced gene expression. One retrospective case series of 50 patients with JDM treated with MMF after suboptimal response to aggressive initial therapy with parenteral steroids and methotrexate showed improvement in both skin and muscle disease activity and a steroid-sparing effect [Dagher et al. 2010] . In a small series of patients with refractory JDM treated with tacrolimus, skin disease, global disease activity and physical function were reported to improve. Patients were able to reduce corticosteroid therapy, and the medication was well tolerated [Hassan et al. 2008 ].
Finally, for extremely severe disease resistant to multiple immunosuppressive therapies, autologous stem-cell transplant has been reported in two children with sustained remission occurring in both patients. However, it is likely that this approach has to be embarked upon before irreversible damage has been acquired to be beneficial [Holzer et al. 2010] .
Nondrug aspects of management
In addition to drug therapy, other key aspects of management of patients with JDM that involve the whole multidisciplinary team are pivotal. Intensive physiotherapy can assist in maintaining and restoring muscle strength and there is evidence that physiotherapy is a safe therapy for muscles in JDM [Maillard et al. 2005] . Use of photo protection for skin, at all times, must be emphasized. Other interventions, such as nasogastric intubation with dysphagia or speech and language therapy with dysphonia, and specialist skin care, may be needed.
Treatment algorithms developed by consensus
Despite the variety of new treatment approaches available for children with JDM, their remains a paucity of prospective RCTs to provide solid evidence on which to base treatment decisions. The rarity of JDM means that for any trial to provide useful information, multicentre collaboration is required. Such trials are vital but also costly and time consuming. An additional method of collecting and comparing therapeutic regimens has been suggested by Huber and colleagues . Three separate algorithms for the initial treatment of moderately severe JDM were developed using international expert opinion and guided by information from the survey of North American practice published by Stringer and colleagues [Stringer et al. 2010 ]. This approach would allow the standardized prospective collection of data comparing treatment approaches, such as the use of IvIg and the route of corticosteroid administration, without requiring a significant change in clinical practice for the majority of paediatric rheumatologists in the UK and North America [Martin et al. 2011b; Stringer et al. 2010] .
Conclusions
The prognosis of JDM and the related childhood IIM has improved dramatically in recent years. Despite this, these conditions remain serious and still potentially life threatening, and since they are so rare, an evidence base for treatment is difficult to build. The long-term comorbidities in children treated in the modern era are as yet unknown, but several reports suggest that these children may be at increased risk of cardiovascular disease in adult life [Schwartz et al. 2011 ]. Central to our ability to compare data and long-term outcomes reliably is the development of an internationally agreed set of core data. Collaborative work towards this, in order to harmonize data collection from centres throughout Europe and America, and then share information on clinical features, biomarkers and response to medication in large numbers of children, remains ongoing.
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